TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Liver function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS on pain movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC A 1.1 section
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic performance of urine TIMP-IGFBP7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Average Daily Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: AUC (Area under plasma concentration-time curve from time zero to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t (Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum observed plasma concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Shoulder Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly number of binge eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly number of purging episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized asthma exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arachidonic acid induced aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of the Ad4-mgag and Ad4-EnvC150 vaccines
Endpoint domain: Adverse events/effects
Primary endpoint: local control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tremor Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Survival of the prosthesis
Endpoint domain: Mortality/survival
Primary endpoint: Number of subjects with fever greater than or equal to 39.1C oral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CAM Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evolution (persistence or resolution)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metastasis in Peritoneum and peritoneal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Endoscopic Remission (SES-CD score of 0-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Performance on the Minimal Assessment of Cognitive Function in MS Battery (MACFIMS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence rate of peri-operative hospital-acquired pressure ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: EEG data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of adverse events leading to treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of severe adverse events leading to treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Carer and Patient Collaboration Scale (CPCS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Short Evaluation of Eating Disorders (SEED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative total methylprednisolone doses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of subjects with insulin independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with scabies a week after first treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with scabies four weeks after second treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transepidermal water loss in gr/hr/m^2 on first week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transepidermal water loss in gr/hr/m^2 on fourth week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Count Change From Baseline to 26 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients With Platelet Count Normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients With Hematologic Normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent reduction in urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Healing of ischemic ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased pain level as reported by the patient
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in IAUC for Postprandial Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: chemical pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in Hamilton Depression Scale (HAMD-6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative incidence of acute mountain sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of pregnant women exposed to SHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of smoker husbands with adequate knowledge of effects of SHS on pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responder Rate of B-Cell Depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients in endoscopic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Interleukin-6 (IL6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morbi-mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Clinical outcomes (mRS) at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of dabigatran etexilate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Lanza score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: growth of microbial agent in culture of joint aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: spectral power of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of scales for the Assessment of Negative Symptoms (SANS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P/F Ratio on Day 3 of Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: bleeding on probing changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache mean intensity variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diaphragmatic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HIA titers of 1:40 or serological response with a four-fold or greater increase in HI antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean micturition frequency within 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in weight-for-length z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St. Mark's (Vaizey) Incontinence Severity Score - Average Change From Baseline Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in proliferation marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral rate for GA-identified deficits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of epiretinal membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Inhibition of mTORC1 and mTORC2 signalling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: remission of rheumatoid arthritis and osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Residual neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants achieving prescribed physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: toxicity of tandem high dose chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Re-hospitalization for Complication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of switch from depression to hypomania, mania, or mixed episode
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluation of Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Hypotensive Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of successful management of maternal hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects with an ACC score of zero
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity towards ADHD clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity towards executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle activity assessed as RMS of amplitude (µV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of untreated illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brachial-ankle pulse wave velocity (ba-PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflow of anaesthetic agents and the relevant concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with ankle or ligaments abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median Number of Daily Voiding Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: patients' perspective of cancer care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wrinkle Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of the device through adverse event reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Children's experiences using the myoelectric device
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration-time Curve of Ibuprofen (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of Ibuprofen in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve of Pseudoephedrine (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of Pseudoephedrine in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal resonance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV-9 vaccine administration rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Highest dose level without unacceptable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Intelligibility phonetic test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and nature of altered phonemes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Glenoid Component Position (Inclination and Version)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Glenoid Component Position (AP and IP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Nodes Identified by ICG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peristomal Skin Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time of operation in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhage control and ease of operation using a visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective assessment of neurosensory function using a probe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radiographic percentage of change in bone defect volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Content validity of the NIH Quality of Life and Symptoms Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Content validity of the EORTC-QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Primary Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Microbiological Outcome at the Test of Cure (TOC) Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: relapse incidence
Endpoint domain: Mortality/survival
Primary endpoint: Area under the sertraline plasma concentration-time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration of sertraline (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aneurysm rupture or growth
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline emotional regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline self-awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline inflammatory gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose proportionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diet Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Assessment of Esophagus Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semiquantitative Assessment of Esophagus Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incretin effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Depression, Anxiety and Stress Scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relative oral bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC 0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokines, chemokines and T cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Alanine aminotransferase (ALAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Time to Clinical Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of repigmentation in vitiligo patches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Acute Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Not requiring long term rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improved function as measured by standardized knee scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Aquapheresis versus Diuretic Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Aquapheresis versus Diuretic Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Delta Sequential Organ Failure Assessment (SOFA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subject preference between traditional paper symptom diary and VOCEL® Mobile Diary
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Children's Sleep Habits Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Eyberg Child Behavior Inventory total problem score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of MISSION Sessions Undertaken
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recognition of ficolin-3-dependent necrotic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RCSQ patient scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increment of radioactive iodine uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Residual Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative hospital stay (days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Full clearance of individual lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peak Plasma Concentration (CMAX) of alprazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of alprazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of PET/MRI system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hearing Handicap Inventory for the Elderly (HHIE-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Tear Osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of symptomatic mesocolic internal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of individuals with mental health disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration-time Curve (AUC[0-inf]) of Nemiralisib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Nemiralisib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-life (t1/2) of Nemiralisib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retropalatal Expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes